qwertyuiopasdfghjklzxcvbnmqwerty

uiopasdfghjklzxcvbnmqwertyuiopasd
fghjklzxcvbnmqwertyuiopasdfghjklzx
cvbnmqwertyuiopasdfghjklzxcvbnmq
wertyuiopasdfghjklzxcvbnmqwertyui
opasdfghjklzxcvbnmqwertyuiopasdfg
hjklzxcvbnmqwertyuiopasdfghjklzxc
vbnmqwertyuiopasdfghjklzxcvbnmq
wertyuiopasdfghjklzxcvbnmqwertyui
opasdfghjklzxcvbnmqwertyuiopasdfg
NIFTY OUTLOOK
hjklzxcvbnmqwertyuiopasdfghjklzxc
REPORT
vbnmqwertyuiopasdfghjklzxcvbnmq
th
22 March 2017
wertyuiopasdfghjklzxcvbnmqwertyui
opasdfghjklzxcvbnmqwertyuiopasdfg
hjklzxcvbnmrtyuiopasdfghjklzxcvbn
mqwertyuiopasdfghjklzxcvbnmqwert
yuiopasdfghjklzxcvbnmqwertyuiopas
 22th March 2017

NIFTY

NIFTY SPOT : R1:9150 R2:9179 R3:9210

PIVOT :9119 S1:9089 S2:9058 S3:9029

NIFTY DAILY CHART

CHART INTERPRETATION

We have now revised the immediate support threshold for the index upwards to 8970 region as it is the
confluence of following: The upper band of previous two weeks consolidation is at 8970,Rising 20-day EMA,
which has acted as intermediate support in the entire up move since December 2016 lows, is placed at 8941. As
per the change of polarity, yearly high of 2016 is at 8968 is likely to reverse its role and act as support, going
forward.
Among oscillators, the short-term 14 period RSI are hovering in overbought territory with readings of 71.

INDEX OUTLOOK

Nifty Future: The Nifty is likely to open flat to negative on the back of week global cues. Its important to
sustain above 9130 to move upwards. Sell Nifty below 9100 for targets of 9050, stop loss: 9140

Nifty Bank Future: The index continued to trade below 21300 but is now facing some support near the 21040
zone. With 8 out of 12 Bank Nifty components ending negative, profit booking may continue at higher levels.
Hence, in the short-term one can look at going short at higher levels. Sell Nifty Bank in the range of 20970-
20960, targets: 20880-20800, stop loss: 21050

WWW.EQUITYRESEARCHLAB.COM
 22th March 2017

SECTORAL INDICES

Key Indices Levels to watch out for the day

INDEX (Spot) RESISTANCE 2 RESISTANCE 1 LTP SUPPORT 1 SUPPORT 2
SENSEX 29850 29675 29485.45 29400 29265
NIFTY 9220 9170 9121.50 9090 9050
NIFTYBANK 21350 21175 21019.00 20890 20700
NIFTYIT 11050 10900 10787.20 10675 10540

CORPORATE NEWS

The USFDA has issued an import alert for Divis Laboratories Visakhapatnam unit-II. The companys
Visakhapatnam unit contributes 60-65% to total sales and 20-21% to US sales. Stock was down 20%.

Dr. Reddy's Laboratories witnessed selling pressure as its Duvvada facility received 13 USFDA observations. The
latest observations are a setback for the company as it dims hopes of new approvals for the US market in the
next year.

Jubilant Life Sciences has announced that its subsidiary Jubilant Pharma will negotiate a potential acquisition
of a specialty business in the US through internal accruals.

WWW.EQUITYRESEARCHLAB.COM
 22th March 2017

ERL RESEARCH TEAM

Member Name Designation E-mail ID

Mr. Tuhinanshu Jain Research Head Tuhinanshu.jain@equityresearchlab.co.in
Mr. Yogesh Subnani Sr. Research Analyst Yogesh.subnani@equityresearchlab.co.in

DISCLAIMER

The information and views in this report, our website & all the service we provide are believed to be
reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have
the right to choose the product/s that suits them the most. Investment in Stocks has its own risks.
Sincere efforts have been made to present the right investment perspective. The information contained
herein is based on analysis and up on sources that we consider reliable. We, however, do not vouch
for the accuracy or the completeness thereof. This material is for personal information and we are not
responsible for any loss incurred based upon it & takes no responsibility whatsoever for any financial
profit s or loss which may arise from the recommendations above. The stock price projections shown
are not necessarily indicative of future price performance. The information herein, together with all
estimates and forecasts, can change without notice.

Equity Research Lab does not purport to be an invitation or an offer to buy or sell any financial
instrument. Analyst or any person related to Equity Research Lab might be holding positions in the
stocks recommended. It is understood that anyone who is browsing through the site has done so at his
free will and does not read any views expressed as a recommendation for which either the site or its
owners or anyone can be held responsible for. Any surfing and reading of the information is the
acceptance of this disclaimer.

Our Clients (Paid or Unpaid), any third party or anyone else have no rights to forward or share our
calls or SMS or Report or Any Information Provided by us to/with anyone which is received directly
or indirectly by them. If found so then Serious Legal Actions can be taken. Any surfing and reading of
the information is the acceptance of this disclaimer.

ALL RIGHTS RESERVED.

WWW.EQUITYRESEARCHLAB.COM